Tumor PD-L1 upregulation reflects negative dynamic immune activities in the TME (Taube et al., 2012; Spranger et al., 2013) and is the premise of anti-PD-1/PD-L1 therapy. This evidence concerns the gene PDCD1 and neoplasm.